Twist Bioscience Corporation (TWST)
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases
Twist Bioscience Corporation reported Q1 2026 revenue of $103.7M, up 17% YoY, and raised full-year guidance to $435–$440M. TWST targets adjusted EBITDA breakeven in Q4 2026, with gross margin expected above 52% for fiscal 2026. The company's DNA synthesis platform and AI-driven growth are promising, but profitability and market size remain concerns.
Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.53 per share a year ago.
Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know
Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Can Twist Bioscience Drop More?
Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.59 per share a year ago.
Twist Bioscience: Headwinds Are Mounting
Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also taken much of the upside off the table. Twist's NGS business continues to be a growth driver, but much of this is already reflected in the share price.
After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST)
The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Responsibility Officer & Senior VP of Corporate Affairs Emily Marine Leproust - Co-Founder, Board Chair & CEO Patrick John Finn - President & COO Conference Call Participants Chad M. Wiatrowski - TD Cowen, Research Division Luke England Sergott - Barclays Bank PLC, Research Division Madeline Kendall Mollman - Wolfe Research, LLC Matthew Richard Larew - William Blair & Company L.L.C.
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.86 per share a year ago.
TWST vs. NTRA: Which Genomics Play Is a Better Buy?
Cathie Wood's Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary biotech innovators that could experience an AI tailwind like few other industries.
